Your Navigation:PCAR > Abstract
Search pcar
Pharmaceutical Care and Research: 2019; 19(2):133-136
DOI: 10.5428/pcar20190214
Drug therapy of the patients with heart failure and hyperuricemia:case reports and literature analysis
1. SONG Yanmei1(1.Department of Pharmacy,Central Hospital of Zaozhuang Mining Group,Shandong Zaozhuang 277800,China
2. LI Xuejing1(1.Department of Pharmacy,Central Hospital of Zaozhuang Mining Group,Shandong Zaozhuang 277800,China )
3. DU Yumeng1(1.Department of Pharmacy,Central Hospital of Zaozhuang Mining Group,Shandong Zaozhuang 277800,China )
4. WANG Sijian1(1.Department of Pharmacy,Central Hospital of Zaozhuang Mining Group,Shandong Zaozhuang 277800,China )
5. ZHANG Weixia2(2.Department of Pharmacy,Ruijin Hospital Affiliated to School of Medicine,Shanghai Jiaotong University,Shanghai 200025,China
ABSTRACT  Objective: To explore the drug treatment regimen for patients with heart failure complicated with hyperuricemia.Methods: Clinical pharmacists participated in the drug treatment of the patients with heart failure complicated with hyperuricemia,and related literature was reviewed and analyzed.Results and Conclusion: There were interactions between heart failure and hyperuricemia.The choice of right drugs could be more beneficial to patients.In the treatment of hyperuricemia,various non-steroidal anti-inflammatory drugs had different effects on pain relief and cardiovascular system.Allopurinol could reduce the incidence of cardiovascular adverse events.Rational choice of drugs for the treatment of heart failure could reduce the level of uric acid,and subsequently reduce the impact of high uric acid on cardiovascular system and the rate of such adverse events as gout.
Welcome to PCAR! You are the number 205 reader of this article!
Please cite this article as:
SONG Yanmei1,LI Xuejing1,DU Yumeng1,WANG Sijian1,ZHANG Weixia2,. Drug therapy of the patients with heart failure and hyperuricemia:case reports and literature analysis[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(2): 133-136.
1. HUANG He,HUANG Baotao,LI Yulin,et al.Uric acid and risk of heart failure:a systematic review and meta-analysis[J].Eur J Heart Failure,2014,16(1):15-24.
2. van Walsem A,Pandhi S,Nixon R M,et al.Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis:a network meta-analysis[J].Arthritis Res Ther,2015,17(1):66.
3. Bally M,Beauchamp M E,Abrahamowicz M,et al.Risk of acute myocardial infarction with real-world NSAIDs depends on dose and timing of exposure[J].Pharmacoepidemiol Drug Saf,2018,27(1):69-77.
4. LI Jun,ZHANG Ying,XU Yi,et al.Allopurinol for ameliorating exercise tolerance of non-hyperuricemic patients with chronic heart failure in 62 cases[J].China Pharmaceuticals,2015,24(14):22-23.In Chinese with English abstract.
5. Bredemeier M,Lopes L M,Eisenreich M A,et al.Xanthine oxidase inhibitors for prevention of cardiovascular events:a systematic review and meta-analysis of randomized controlled trials[J].BMC Cardiovasc Disord,2018,18(1):24-34.
6. Ogino K,Kato M,Furuse Y,et al.Uric acid-lowering treatment with benzbromarone in patients with heart failure:a double-blind placebo-controlled crossover preliminary study[J].Circ Heart Fail,2010,3(1):73-81.
7. LI Kang,HU Weixin.HLA-B*5801 gene and allopurinol induced adverse events[J].Chin J Nephrol Dial Transplant,2014,23(6):553-558. In Chinese with English abstract.
8. Otani N,Ouchi M,Hayashi K,et al.Roles of organic anion transporters(OATs) in renal proximal tubules and their localization[J].Anat Sci Int,2017,92(2):200-206.
9. Cabrera S E,Edwards N C,Steeds R P,et al.Spironolactone increases serum uric acid levels in patients with chronic kidney disease[J].J Hum Hypertens,2014,28(3):210-211.
10. ZHANG Dan,TAN Hong,LI Yuehua,et al.Efficacy and safety of tolvaptan in treating heart failure[J].China Med,2016,11(4):469-473.In Chinese with English abstract.
11. Ueno S,Hamada T,Taniguchi S,et al.Effect of antihypertensive drugs on uric acid metabolism in patients with hypertension:cross-sectional cohort study[J].Drug Res,2016,66(12):628-632.
12. FAN Yu,WEI Feifei,LANG Yakun,et al.Losatan treatment for hypertensive patients with hyperuricaemia in Chinese population:a meta-analysis[J].J Hypertens,2015,33(4):681-688.
13. ZHANG Jinchun.Clinical observation of valsartan in the treatment of essential hypertension associated with hyperuricemia[J].China Med Pharm,2015,5(4):52-54.In Chinese with English abstract.
14. ZHANG Yuqing,Neogi T,Chen C,et al.Low-dose aspirin use and recurrent gout attacks[J].Ann Rheum Dis,2014,73(2):385-390.
15. ZHANG Shiqing,ZHU Yonghong.Pathogenesis and treatment strategy of elevated blood uric acid caused by ticagrelor[J].Chin J Evid Based Cardiovasc Med,2016,8(4):511-512.In Chinese.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330